Beyond Radiochemistry: An Integrated Translational Blueprint for the Next Generation of Radionuclide Ligand...

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Radionuclide ligand conjugates (RLCs) show promise in oncology for therapy and theranostics.
• Current RLC development often treats targeting ligand, chelator, and radionuclide as separate components.
• Clinical success depends on complex interactions including target density, distribution, internalization, and resistance.

Purpose of the Study:

• To address the translational challenge of expanding RLCs beyond current limitations.
• To advocate for an integrated biologic design framework over modular radiochemistry.
• To propose a new development strategy for next-generation RLCs.

Main Methods:

• Analysis of the limitations of the conventional ligand-chelator-payload model.
• Identification of key barriers to RLC expansion: biologic stratification, isotope-disease matching, and resistance integration.
• Proposal of a blueprint for next-generation RLC development.

Main Results:

• The conventional model is insufficient for broad clinical generalization.
• Inadequate biologic stratification, poor isotope-disease matching, and limited resistance integration hinder RLC expansion.
• A new framework is proposed focusing on target biology, disease context, and combination strategies.

Conclusions:

• Next-generation RLC development must integrate target biology, ligand pharmacology, and isotope physics.
• Overcoming current barriers requires biologically prioritized targets, disease-contextual isotope selection, and biomarker-guided combinations.
• This reframing aims to establish RLCs as a scalable precision oncology platform.